Transcatheter aortic valve implantation with Core Valve: First Indian experience of three high surgical risk patients with severe aortic stenosis  by Seth, Ashok et al.
ww.sciencedirect.com
i n d i a n h e a r t j o u rn a l 6 5 ( 2 0 1 3 ) 3 9 5e3 9 9Available online at wjournal homepage: www.elsevier .com/locate/ ih jOriginal ArticleTranscatheter aortic valve implantation with Core
Valve: First Indian experience of three high surgical
risk patients with severe aortic stenosisAshok Seth*, Vishal Rastogi, Vijay Kumar, Syed Maqbool,
Arif Mustaqueem, V. Ravi SekarFortis Escorts Heart Institute, New Delhi, Indiaa r t i c l e i n f o
Article history:
Received 14 March 2013
Accepted 19 June 2013
Available online 9 July 2013
Keywords:
Aortic stenosis
TAVI
Core Valve
First Indian
Structural Heart Disease* Corresponding author. Chairman, Fortis Es
01126825058.
E-mail address: ashok.seth@fortishealthc
0019-4832/$ e see front matter Copyright ª
http://dx.doi.org/10.1016/j.ihj.2013.06.003a b s t r a c t
The prevalence of aortic stenosis is increasing with aging population. However with
multiple co-morbidities and prior procedures in this aging population, more and more
patients are being declared unfit for the ‘Gold Standard’ treatment i.e. surgical aortic valve
replacement (AVR). Among the patients who are unfit or high risk for aortic valve
replacement (AVR) by open heart surgery, transcatheter aortic valve implantation (TAVI)
has been proven to be a valuable alternative improving survival and quality of life. We
report first Indian experience of Core Valve (Medtronic Inc.) implantation in three high
surgical risk patients performed on 22nd and 23rd February 2012.
Copyright ª 2013, Cardiological Society of India. All rights reserved.1. Introduction For these patients, who are at high surgical risk, a less invasiveTraditionalaorticandmitral surgeryhavebeenthemainstayof
treatment for valvular heart disease; prior to surgical tech-
niques for valve replacement and repair, there were no effec-
tive therapies for patients with severe disease. In selected
patients at experienced centers with expert surgeons, the re-
sults have generally been excellent with improved morbidity
and mortality compared with medical therapy but at a cost of
significant invasiveness and recovery time for the patient.1 In
clinical practice, at least 30% of patients with severe symp-
tomatic aortic stenosisdonotundergosurgery for replacement
of the aortic valve, owing to advanced age, left ventricular
dysfunction, or the presence ofmultiple coexisting conditions.corts Heart Institute, Okh
are.com (A. Seth).
2013, Cardiological Societtreatment may be a worthwhile alternative. Transcatheter
aortic valve implantation (TAVI) is a newprocedure, inwhich a
bioprosthetic valve is inserted through a catheter and
implanted within the diseased native aortic valve. Since 2002,
whentheprocedurewasfirstperformed, therehasbeena rapid
growth in its use throughout the world for the treatment of
severe aortic stenosis in patientswho are at high surgical risk.22. Case 1
Mrs. AD, 80 years old lady, who had undergone coronary
bypass grafting twelve years ago for unstable angina withla Road, New Delhi 110025, India. Tel.: þ91 01147134289; fax: þ91
y of India. All rights reserved.
Fig. 2 e Marker PigTail used for measurements of aortic
root, annulus and height of coronary ostia during
Aortography (RAO caudal).
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chest pain, CCS class III. On evaluation, she was found to have
severe calcific aortic stenosis e aortic valve area by continuity
equation as 0.5 cm2, mean pressure gradient across aortic
valve of 62 mmHg and mild aortic regurgitation. The left
ventricular ejection fraction was 55%. CT coronary angiog-
raphy revealed patent grafts and a Porcelain Aorta. EuroScore
risk for AVR was 32.7%. Surgical AVR was refused on account
of high surgical and anesthesia risks.
The evaluation for TAVI using Core Valve (Medtronic Inc.)
was done according to the set guidelines of clinical and im-
aging work up protocols. Imaging by Transthoracic echocar-
diography, Transesophageal echocardiography and CT scan
were performed apart from the invasive coronary angiog-
raphy3,4 (Figs. 1e5). Key parameters of Imaging from TAVI
work up perspective include aortic valve and Root analysis,
coronary ostia length and peripheral vascular access vessel
anatomy. The Core Valve size selection dependsmainly on the
aortic annulus perimeter and diameter detected on CT
Aortography as well as Transesophageal echocardiography.
Based on these measurements, 26 mmCore Valve was chosen
for this patient.2.1. The device
Core Valve consists of three porcine pericardial tissue leaflets
mounted on a self expanding nitinol frame. It is available in
three sizes viz 26 mm, 29 mm and 31 mm. When appropriate
size is chosen, it provides good hemodynamic in most of the
diseased aortic valves with complex anatomies.2.2. Technique of implantation5e8
The patient underwent TAVI through the transfemoral route.
In this approach, the vascular access was taken via surgical
cut down of the right common femoral artery and closure of
the vascular access was also achieved surgically.Fig. 1 e PLAX view in Transthoracic echocardiography for
making different measurements at the aortic root and
annulus.Two teams worked during the procedure simultaneously,
one team prepared the Core Valve (crimping the valve under
ice cold water and mounting it on the delivery catheter) to be
ready for implantation while the operating team indulged in
obtaining access, valvuloplasty and finally valve deployment.
The procedure was carried out under general anesthesia. The
deployment steps include the crossing of aortic valve, balloon
aortic valvuloplasty to dilate the native valve and positioning
the prosthesis at the level of the aortic valve. It is important to
perform valvotomy only after confirmation from the team
who is mounting the Core Valve that they are ready with the
valve as sometimes during valvotomy, patient may develop
acute severe aortic regurgitation with hemodynamic
compromise necessitating urgent valve deployment. TheFig. 3 e Marker PigTail used for measurements of aortic
root, annulus and height of coronary ostia during
Aortography (LAO cranial).
Fig. 4 e CT scan measurements of aortic root and annulus.
Fig. 6 e Core Valve deployment under fluoroscopy and TEE
guidance.
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step and done under fluoroscopy with the aid of calcification
present on the valve serving as a guide in defining the level at
which the deployment is done. Frequent Aortography in-
jections by a pigtail catheter placed in aortic root are used to
determine the position of the valve and the plane of alignment
of the aortic cusps. Transesophageal echocardiography was
also used as an additional confirmation modality of the valve
position. Once correct position was confirmed, the prosthesis
was released. Aortography and check coronary angiography
shoots were performed after TAVI to confirm the position of
the deployed prosthesis and the coronary artery patency.
Transesophageal echocardiography confirmed the location of
valve, aortic prosthesis regurgitation, and patency of coronary
arteries. Hemopericardium and aortic dissection are other
important complications to be ruled out.
2.3. Result
The hemodynamic performance of the prosthesis was
assessed using pressure recordings and echocardiography.Fig. 5 e Reconstructed multidetector computed
tomographic images of the abdominal aorta and its pelvic
branches for demonstration of tortuosity and calcific
atherosclerosis essential for evaluation of access vessel
anatomy work up.Patient had no significant transvalvular gradient and mild
aortic regurgitation. After the procedure, the patient stayed
in intensive care for 48 h and was closely monitored for
vascular access, and rhythm disturbances, especially late
atrioventricular block. She showed satisfactory recovery and
was discharged on 29th February on dual antiplatelet
treatment.
She is very active and asymptomatic on eight months
follow up.Fig. 7 e Deployed Core Valve 26 mm.
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Mr. PNM, 72 years gentleman with history of Coronary artery
bypass surgery in the year 2000 was evaluated for recurrence
of angina on exertion class III and dyspnea NYHA Class III.
Echocardiography showed critical aortic stenosis with valve
area of 0.3 cm2 and mean pressure gradient of 86 mmHg. A
coronary angiography was done which revealed patent grafts.
His EuroScorewas 29.6%. Awork upwas done according to the
set protocol of TAVI evaluation to determine anatomy of
aortic valve, aorta and access route vessels. He underwent
TAVI using 29 mm Core Valve (Medtronic Inc.) via retrograde
femoral approach on 23.02.2012. The procedure was success-
fully done under angiography and Transesophageal echocar-
diographic guidance under general anesthesia. He was
discharged in asymptomatic and stable condition on
29.02.2012.
He continued to remain asymptomatic from cardiac
viewpoint on six-month follow up. Unfortunately, the patient
died of acute bacterial meningitis a month after that.4. Case 3
Mr. GPM, an octogenarian of 81 years age, who had a history
of coronary artery bypass surgery done in the year 2003,
presented to our hospital with symptoms of dyspnea NYHA
class III. Evaluation at our institute revealed severe aortic
valve stenosis as the underlying etiology. The coronary
angiography done after admission revealed patent grafts.
Transcatheter aortic valve implantation was chosen as the
modality of treatment option in view of the increased risk of
surgery at his age and frailty. The work up for TAVI was
done by set protocol. Transcatheter aortic valve implanta-
tion with 29 mm Core Valve was done successfully. On
second day after the procedure, patient developed asymp-
tomatic complete heart block, which was picked up on
telemetry. A dual chamber pacemaker implantation had to
be done on 27.02.2012. The patient was discharged from the
hospital on 02.03.2012 in good health and stable condition.
He is asymptomatic and active at six and nine month
follow-up. His mean gradient across the aortic valve is
11 mmHg with mild aortic regurgitation.
4.1. Discussion
Patients with severe calcific aortic stenosis who carry very
high anesthesia and surgical risk for open heart surgery can
be helped by this interventional technique of valve implan-
tation. The twomain access routes of implantation constitute
transfemoral and transapical routes. The valves implanted
across the world in different major studies are the Core Valve
from Medtronic and the Sapient valve from Edward Life Sci-
ences. Second generation valves are also being studied. More
than 50,000 TAVI procedures have been performed worldwide
and now we have numerous single center reports and regis-
tries as sources of information.9e13 The patients treated were
mostly over 80 years old, at high risk (e.g., Logistic EuroScore
>20% in most cases), or with contraindications for surgery.Procedural success is over 90% in experienced centers and in
the most recent registries. These valves perform well with a
final valve area ranging from 1.5 to 1.8 cm2 and mean gradi-
ents around of 10 mmHg, which is at least equivalent to that
of a surgically implanted prosthesis. Interestingly, recent
observations using Multi slice CT scan showed that in up to
20% of cases, the shape of the prosthesis may be elliptic after
implantation, which may favor paravalvular aortic regurgi-
tation. Mortality at 30 days ranges from 5e18% for the
transfemoral approach, and 10e19% when using the trans-
apical approach. Coronary obstruction is a rare (<1%) but
dramatic complication. It may be due to external compres-
sion of the left main coronary artery by bulky valve calcifi-
cation or obstructive low positioned coronary ostia. Acute
myocardial infarction occurs in 2e5% of cases. Mild aortic
regurgitation, mostly paravalvular, is observed in over 50% of
the cases, and moderate regurgitation occurs in around 20%
of the cases. The availability of larger prostheses and their
more careful matching with the size of the aortic annulus, in
order to slightly oversize the device, has led to a decrease in
the incidence of severe aortic regurgitation to <10%. Pros-
thesis embolization is rare, around 1%. Stroke rate ranges
from 2e9% with a trend towards a lower incidence of stroke
when using the transapical approach. Vascular complications
remain a significant cause of morbidity in the transfemoral
approach, with an incidence ranging from 10e15% with the
self expanding device, decreasing to 2e4% with decreasing
profile of devices. Atrioventricular block occurs in 4e8% of
cases with the balloon expandable devices and up to 30%with
self expandable devices, necessitating pacemaker implanta-
tion. The presence of previous right bundle branch block and
the onset of left bundle branch block during the procedure are
predictors of the need for pacemaker implantation after TAVI.
Finally, the transapical approach, which requires a thoracot-
omy and ventriculotomy, may lead to specific postoperative
complications as well as rare left ventricular apical aneu-
rysms. Surgical conversion is rare but requires the immediate
availability of cardiac support and surgical back up, at least in
operable patients, in cases of life threatening complications
such as coronary occlusion, massive aortic regurgitation or
valve migration in the left ventricle. A learning curve effect is
there on the success rate. Long-term results up to six years
(though only one to a maximum of three years in most
studies) show a survival rate of 70% at one year and 60% at
two years, with a significant improvement in clinical condi-
tion and quality of life parameters in most cases, which is of
utmost importance in this elderly population. Anecdotal
cases of valve endocarditis or thromboembolism have been
reported. The risk of bleeding could be a concern in elderly
patients when receiving a combination of antiplatelet agents.
The degree of aortic regurgitation remains stable over time
and mild to moderate aortic regurgitation did not require
re-intervention or cause severe hemolysis during limited
follow-up. Serial echocardiographic studies have consistently
shown good prosthetic valve function and no structural
deterioration of valve tissue has been reported. Left ventric-
ular ejection fraction improves after TAVI, while the degree of
functional mitral regurgitation decreases. There are no
studies comparing either one device against the other or one
approach with the other. Valve in a valve implantation for
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regurgitation or for degenerated valve prostheses, either
stented or stent-less is also feasible, however, it is too early to
draw any definite conclusions on this attractive potential
indication.4.2. Conclusion
Transcatheter aortic valve implantation (TAVI) done suc-
cessfully in these three patients in our institution is the first
ever experience in India. It represents the first series of Core
Valve implantation in our country and gives an impetus to
the TAVI programme here. High surgical risk patients can
now be safely treated with this new modality of percuta-
neous valve replacement therapy. It is a very exciting leap in
the field of Interventional treatment with respect to struc-
tural heart disease therapies, going in parallel with world
trends.Conflicts of interest
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